Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Apr;35(4):672–678. doi: 10.1128/aac.35.4.672

Ceftazidime as monotherapy or combined with teicoplanin for initial empiric treatment of presumed bacteremia in febrile granulocytopenic patients.

I Nováková 1, J P Donnelly 1, B De Pauw 1
PMCID: PMC245077  PMID: 1829879

Abstract

In a prospective randomized study, 120 febrile, granulocytopenic patients received as initial therapy ceftazidime with or without teicoplanin. At the onset of fever, patients had no obvious infectious focus. For 103 assessable episodes, initial bacteremias were detected in 18 of 51 patients (35%) given ceftazidime and 20 of 52 patients (38%) given the combination; 13 and 17 bacteremias caused by gram-positive bacteria occurred in these groups, respectively. There was no difference in terms of the final response (25 of 51 patients [49%] treated with ceftazidime alone versus 33 of 52 patients [63%] given the combination), and the morbidity was comparable for both treatment groups. The duration of fever and of total antibiotic therapy were similar in both groups. Initial therapy was modified in 26 patients (51%) treated with ceftazidime, with 20 surviving the infection, and in 19 patients (37%) treated with the combination, with 15 surviving. Persistent fever was the main reason for changing treatment, and no patient died of a gram-positive infection. Subsequent infective events occurred in 16 patients (31%) given ceftazidime and in 25 patients (48%) given the combination. Lung infiltrates developed in 12 and 13 patients, respectively, but more new infections occurred in the combination group. Allergic skin reactions were also more frequent in this group. Thus, while teicoplanin provides simple, reliable, and safe treatment of patients with presumed gram-positive infections, it is not useful when given empirically to this patient population, and treatment may result in more infective complications and adverse events.

Full text

PDF
672

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Babul N., Pasko M. Teicoplanin: a new glycopeptide antibiotic complex. Drug Intell Clin Pharm. 1988 Mar;22(3):218–226. doi: 10.1177/106002808802200309. [DOI] [PubMed] [Google Scholar]
  2. Cohen J., Donnelly J. P., Worsley A. M., Catovsky D., Goldman J. M., Galton D. A. Septicaemia caused by viridans streptococci in neutropenic patients with leukaemia. Lancet. 1983 Dec 24;2(8365-66):1452–1454. doi: 10.1016/s0140-6736(83)90799-7. [DOI] [PubMed] [Google Scholar]
  3. Dekker A. W., Rozenberg-Arska M., Verhoef J. Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin. Ann Intern Med. 1987 Jan;106(1):7–11. doi: 10.7326/0003-4819-106-1-7. [DOI] [PubMed] [Google Scholar]
  4. Del Favero A., Menichetti F., Guerciolini R., Bucaneve G., Baldelli F., Aversa F., Terenzi A., Davis S., Pauluzzi S. Prospective randomized clinical trial of teicoplanin for empiric combined antibiotic therapy in febrile, granulocytopenic acute leukemia patients. Antimicrob Agents Chemother. 1987 Jul;31(7):1126–1129. doi: 10.1128/aac.31.7.1126. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dickinson G. M., Bisno A. L. Infections associated with indwelling devices: concepts of pathogenesis; infections associated with intravascular devices. Antimicrob Agents Chemother. 1989 May;33(5):597–601. doi: 10.1128/aac.33.5.597. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fainstein V., Bodey G. P., Bolivar R., Elting L., McCredie K. B., Keating M. J. Moxalactam plus ticarcillin or tobramycin for treatment of febrile episodes in neutropenic cancer patients. Arch Intern Med. 1984 Sep;144(9):1766–1770. [PubMed] [Google Scholar]
  7. Hermans P. E., Wilhelm M. P. Vancomycin. Mayo Clin Proc. 1987 Oct;62(10):901–905. doi: 10.1016/s0025-6196(12)65046-0. [DOI] [PubMed] [Google Scholar]
  8. Jones P. G., Rolston K. V., Fainstein V., Elting L., Walters R. S., Bodey G. P. Aztreonam therapy in neutropenic patients with cancer. Am J Med. 1986 Aug;81(2):243–248. doi: 10.1016/0002-9343(86)90258-5. [DOI] [PubMed] [Google Scholar]
  9. Karp J. E., Dick J. D., Angelopulos C., Charache P., Green L., Burke P. J., Saral R. Empiric use of vancomycin during prolonged treatment-induced granulocytopenia. Randomized, double-blind, placebo-controlled clinical trial in patients with acute leukemia. Am J Med. 1986 Aug;81(2):237–242. doi: 10.1016/0002-9343(86)90257-3. [DOI] [PubMed] [Google Scholar]
  10. Karp J. E., Merz W. G., Hendricksen C., Laughon B., Redden T., Bamberger B. J., Bartlett J. G., Saral R., Burke P. J. Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1987 Jan;106(1):1–7. doi: 10.7326/0003-4819-106-1-1. [DOI] [PubMed] [Google Scholar]
  11. Kern W., Kurrle E., Vanek E. High risk of streptococcal septicemia after high dose cytosine arabinoside treatment for acute myelogenous leukemia. Klin Wochenschr. 1987 Aug 17;65(16):773–780. doi: 10.1007/BF01743253. [DOI] [PubMed] [Google Scholar]
  12. Klastersky J., Zinner S. H., Calandra T., Gaya H., Glauser M. P., Meunier F., Rossi M., Schimpff S. C., Tattersall M., Viscoli C. Empiric antimicrobial therapy for febrile granulocytopenic cancer patients: lessons from four EORTC trials. Eur J Cancer Clin Oncol. 1988;24 (Suppl 1):S35–S45. [PubMed] [Google Scholar]
  13. Nováková I. R., Donnelly J. P., Verhagen C. S., De Pauw B. E. Teicoplanin as modification of initial empirical therapy in febrile granulocytopenic patients. J Antimicrob Chemother. 1990 Jun;25(6):985–993. doi: 10.1093/jac/25.6.985. [DOI] [PubMed] [Google Scholar]
  14. Rubin M., Hathorn J. W., Marshall D., Gress J., Steinberg S. M., Pizzo P. A. Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med. 1988 Jan;108(1):30–35. doi: 10.7326/0003-4819-108-1-30. [DOI] [PubMed] [Google Scholar]
  15. Shenep J. L., Hughes W. T., Roberson P. K., Blankenship K. R., Baker D. K., Jr, Meyer W. H., Gigliotti F., Sixbey J. W., Santana V. M., Feldman S. Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer. N Engl J Med. 1988 Oct 20;319(16):1053–1058. doi: 10.1056/NEJM198810203191604. [DOI] [PubMed] [Google Scholar]
  16. Verbist L., Tjandramaga B., Hendrickx B., Van Hecken A., Van Melle P., Verbesselt R., Verhaegen J., De Schepper P. J. In vitro activity and human pharmacokinetics of teicoplanin. Antimicrob Agents Chemother. 1984 Dec;26(6):881–886. doi: 10.1128/aac.26.6.881. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Verhagen C., de Pauw B. E., Donnelly J. P., Williams K. J., de Witte T., Janssen T. H. Ceftazidime alone for treating Pseudomonas aeruginosa septicaemia in neutropenic patients. J Infect. 1986 Sep;13(2):125–131. doi: 10.1016/s0163-4453(86)92813-6. [DOI] [PubMed] [Google Scholar]
  18. Wade J. C., Schimpff S. C., Newman K. A., Wiernik P. H. Staphylococcus epidermidis: an increasing cause of infection in patients with granulocytopenia. Ann Intern Med. 1982 Oct;97(4):503–508. doi: 10.7326/0003-4819-97-4-503. [DOI] [PubMed] [Google Scholar]
  19. Whimbey E., Kiehn T. E., Brannon P., Blevins A., Armstrong D. Bacteremia and fungemia in patients with neoplastic disease. Am J Med. 1987 Apr;82(4):723–730. doi: 10.1016/0002-9343(87)90007-6. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES